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Abstract 
 
DOES INCREASING FLOW TO A HIGH FLOW NASAL CANNULA AFFECT 
MEAN AIRWAY PRESSURE IN AN IN VITRO MODEL? 
 
Introduction:  High-flow nasal cannulas (HFNC) have become popular with many 
institutions for administration of oxygen (O2).  HFNCs are also being used in pediatric 
and neonatal populations for administration of continuous positive airway pressure 
(CPAP) as a treatment for respiratory distress.  Adult patients are being treated with 
HFNCs in a effort to provide a high percentage of O2 and correct hypoxemia and other 
related conditions.  The purpose of this study was to examine the effect of increasing 
flow via a HFNC to an in vitro model to examine the effect of flow on mean airway 
pressure (MPAW). 
Method:  An in vitro model to simulate non-labored and labored spontaneous 
breathing was developed using a Michigan Instrument Laboratory Test and Training 
Lung (MIL TTL) driven by a Hamilton Galileo ventilator to produce a negatively based, 
inspired tidal volume. Flow was introduced to the MIL TTL via a 41 French double 
lumen endotracheal tube.  Airway pressure measurements were observed via a pressure 
monitoring port placed between the MIL TTL and the endotracheal tube and connected to 
the auxiliary pressure monitoring port located on the front of the Galileo ventilator.  A 
Vapotherm 2000i with adult transfer chamber and adult cannula, a Fisher Paykel 
Optiflow, and a generic HFNC consisting of a concha column and a Salter labs high-flow 
cannula were tested at 20, 30, and 40LPM flowrates.  Data was recorded using two 
respiratory rates (12 and 24) and two peak flowrates (35 and 65LPM) to simulate non-
labored and labored breathing.  All other parameters were unchanged and the I:E ratio 
was consistent. 
Data Analysis:  SPSS 16.0 for Windows was used to analyze all data for this 
study.  Descriptive statistics, one-way analysis of variance (ANOVA), and post hoc 
Bonferroni was used for this study.  A p value less than 0.05 were considered significant.  
Results:  Average MPAW for all devices were increased at all three flowrates.  
MPAW was highest at 40LPM flow producing 3.1cmH2O averaged for all HFNCs and 
both respiratory patterns.  The difference in MPAW produced by the three HFNCs were 
also significant with at p=0.000 at all flow rates.  Post hoc Bonferroni adjusted 
probabilities further showed all device comparisons significant except for Vapotherm-
Vapotherm Labored at 30 and 40 LPM flow rates and Vapotherm-Generic Labored at 20 
LPM at  p<0.05.  These three comparisons were at p>0.05 and were statistically equal.  
The generic HFNC produced the highest MPAW (3.5cmH2O).   
Conclusion:  Increased flow via a HFNC does increase MPAW.  The Vapotherm, 
Optiflow, and generic HFNC did not produce the same level of MPAW in this study.
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Chapter I 
Introduction 
Oxygen (O2) therapy is a simple task taught in the first days of respiratory therapy 
education.  The importance of O2 therapy is often overlooked by respiratory therapists 
(RTs) who focus on other technical procedures.  The indications for use are dictated by 
signs and symptoms directly observed by caregivers.  Oxygen is considered a drug thus 
requiring a physician's order to prescribe it and a licensed practitioner to administer it.  
However, the reality of O2 therapy is that it is often neglected until a patient's condition 
worsens to a point that requires very high amounts or alternative methods of delivering it.  
New methods of delivering oxygen via nasal cannula style devices have been gaining 
popularity (Waugh & Granger, 2004).  Devices range from simple and affordable to 
specialized with high humidity.  Humidification systems have become more efficient 
allowing higher flows to be administered.  Patient comfort and tolerability has been 
improved for patients not able to cope with oxygen masks.  As new technology leads to 
the development of new oxygen delivery tools, RTs must alter their focus on an 
overlooked therapy and learn to adapt high flows and high humidity to treat respiratory 
disease processes.  RTs must learn when to correctly use these new methods of high-flow 
delivery to better serve the patients and the health care centers. 
There are many reasons to examine high flow oxygen therapy.  Health care 
centers across the country are focused on shorter stays and infection prevention.  Fiscal 
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shortfalls have forced many hospitals and clinics to look for alternative therapies for 
treatment.  Hospital acquired infection (HAI) has become a major motivator for change in 
practices.  With the proper use of high-flow therapy in patients with adult respiratory 
distress syndrome (ARDS), acute cardiogenic pulmonary edema (ACPE), or chronic 
obstructive pulmonary disease (COPD), patients may have the opportunity to reduce the 
need for more invasive procedures such as mechanical ventilation or bi-level positive 
airway pressure (BiPAP).  The net result of this is less opportunities for patients to 
develop HAI which can increase the length of stay (LOS). 
Mortality rates vary among different disease states.  ACPE has a mortality rate of 
21% (Fiutowski, Waszyrowski, Krzeminska-Pakula, & Kasprzak, 2008).  When ACPE 
requires mechanical intervention and is complicated with myocardial infarction (MI), the 
mortality rate increases to 67% (Fiutowski et al., 2008).  ARDS also has an exceptionally 
high mortality rate; however, studies have shown some variance.  When averaged, the 
pooled mortality rate for ARDS is 43% (Zambon & Vincent, 2008).  Attributed to this 
high mortality rate is difficulty in treating ARDS and the complications that occur with 
positive pressure ventilation (PPV).   COPD is a costly pathology both fiscally and in the 
number of lives lost.  COPD is currently the fifth leading cause of death in the United 
States and is expected to rise to the third leading cause of death by 2020 (Ai-Ping, Lee, & 
Lim, 2005).  COPD exacerbations are a leading cause of hospitalizations in the United 
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States.  The average cost per COPD patient per year who suffers an exacerbation and 
becomes hospitalized is $6000 (Ai-Ping et al., 2005). 
The primary administration route with high flow oxygen is with a nasal cannula.  
This method is minimally obstructive and best tolerated by all patient populations.  The 
nasal cannula has required some modification for high flow application.  Larger bores, 
light weight materials, and adaptability to different flow generators are some of the 
modifications that have occurred.   
High flow nasal cannulas (HFNC) mode of operation has been questioned in the 
literature.  Is it the oxygen that elicits the positive effects of high flow therapy or is it the 
pressure generated by the high flow (Finer, 2005)?  Either factor has led to HFNCs 
becoming very popular among neonatal and pediatric populations.  High flow therapy has 
demonstrated a clear therapeutic advantage in these populations reducing the need for 
invasive respiratory machinery.  But, is it possible to achieve a reduction of invasive 
respiratory procedures in the adult population with the use of HFNCs?  If possible this 
would provide a cost efficient tool to treat respiratory distress.    
Research is needed to determine the effect high flow has on adult patients.  There 
is a need to determine flow-rates so that flow from these devices may be used 
appropriately and quickly.  Pressure generated from high flow devices must be 
determined so patient selection can occur.  The education for respiratory staff must also 
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be adequate as high flows alter breathing mechanics.  The view of O2 therapy must 
change from a supportive modality to an interventional therapy with the use of HFNCs. 
Purpose 
The purpose of this study was to examine the effect of nasal high flow gas therapy 
on mean airway pressure (MPAW) in adult patients.  The experimental study will be 
carried out in vitro in lieu of using human subjects.  Much can be learned by investigating 
what happens when gas flow is manipulated to determine the effect of MPAW.   
Study Questions 
Two questions were addressed by the study.  Does increasing flow increase MPAW 
in an adult breathing model?  The devices used in this study were the Vapotherm 2000i, 
the Optiflow, and a nasal cannula device fabricated from general stock of a respiratory 
care department.  The results obtained from the 3 units were examined to determine if the 
devices yielded the same results.  
Significance 
The product of high flow rates in spontaneous breathing persons is unknown.  By 
using an in vitro lung model in this study, it was possible to isolate the effect of high 
flowrates during negative pressure ventilation.  This study compared two commercial 
products and a fabricated high flow system from standard respiratory stock to determine 
if all 3 devices produced the same effect.  This provided MPAW readings that could be 
suggestive of actual pressures experienced by patients who utilize this therapy.  This 
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study controlled all variables including respiratory time constants allowing the 
computation of mean airway pressure. 
  
 6 
 
Chapter II 
A Review of Literature 
  The literature used to perform this literature review covers multiple areas:  Low 
flow therapy, high flow therapy, neonatal and pediatric respiratory care, humidified high 
flow nasal oxygen, Vapotherm, and Optiflow.  Literature was obtained using PubMed, 
CINAHL, and Web of Science using search terms such as Vapotherm, high flow nasal 
cannula, humidified high flow nasal cannula, high flow oxygen, and Optiflow.  Very few 
studies were found with regards to adult use.  Data from neonatal and pediatric studies 
were used for comparative means.  The literature search was limited to the last 15 years; 
however, literature from other countries will be used due to the lack of research in this 
area on adult subjects.  
Low Flow Therapy 
Low flow oxygen therapy (LFT) is practiced in every hospital in the United 
States.  Administration of low flow therapy (LFT) includes devices such as nasal 
cannulas, simple masks, and partial and non rebreather masks.  Low flow oxygen devices 
provide fixed flows that can result in a fraction of inspired oxygen (FiO2) that is "neither 
precise or predictable" (Branson, Hess, & Chatburn, 1995, p. 56).  People who are 
oxygen sensitive can be affected by the non-precise FiO2 concentration especially in the 
COPD population.  It is known that if hypoxic drive is eliminated the result is death.  
Branson et al. (1995) state the accepted FiO2 for a 6 liter per minute (LPM) nasal cannula 
is 44%.  However, current studies focusing on oxygen (O2) concentrations suggest 
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otherwise.  According to one report, a 6LPM nasal cannula produces a FiO2 between 36-
66% with a mean of 47.9% (Wettstein, Shelledy, & Peters, 2005).  This was performed 
with a closed mouth breathing technique.  Individuals within the study achieved a higher 
FiO2 while breathing with their mouth open compared to those who breathed with their 
mouths closed.  The results from open mouth breathing at a liter flow of 6LPM were 40-
86% with a mean of 59.6% (Wettstein, et al., 2005).  Previous studies have not agreed on 
the effect of open mouth/closed mouth on FiO2.  Wettstein's et al. (2005) methodology 
attempted to correct criticism of previous studies.  Contrary to name, a high flow nasal 
cannula system (6-15LPM) does not use a blender for gas mixing and falls into the low 
flow category.  The reason is due to a variable FiO2 dependent upon patient breathing 
style.  The same principle discussed above applies to cannula systems that use flows 
higher than 6LPM.  Wettstein's et al. (2005) results found means of 69.8% and 80.6% on 
a Salter Labs high flow nasal cannula with closed mouth and open mouth techniques 
respectively.   Because the Salter Labs high flow nasal cannula is limited to 15LPM flow 
and by definition is a low flow device, it will not be used in this study.  A closer 
examination of high flow therapy will occur in the following section. 
High Flow Therapy 
High flow therapy (HFT) is a smaller part of O2 therapy.  High flow devices 
provide a fixed FiO2 independent of the flow which provides a known FiO2 at all times 
(Branson, Hess, & Chatburn, 1995).  High flow cannula systems such as the Vapotherm 
and the Optiflow use a source gas from a blender to feed the system providing a precise 
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FiO2 regardless of the patients breathing style or pattern.  Traditional HFT devices such 
as the air entrainment mask or venti-mask use a manufactured air entrainment port to mix 
oxygen with entrained room air to provide a calculated and predictable FiO2.   HFT has 
been the standard for hypoxic drive patients.  Due to controlled FiO2, predictable oxygen 
delivery to the patient can be monitored; therefore, the partial pressure of oxygen in 
arterial blood (PaO2) threshold remains intact.  The high flow nebulizer (HFN) device is 
if often used with face tents or aerosol face masks and has been used in the post 
anesthesia care units (PACU) for years.  The advantage is that it provides humidity and 
precise oxygen control.  High flow systems as Vapotherm 2000i have been proven to 
provide a very reliable FiO2 in patients who have high respiratory rates and increased 
work of breathing (Wagstaff & Soni, 2007). 
Vapotherm 2000i 
An oxygen delivery device produced by Vapotherm 
(Vapotherm, Annapolis, Maryland) has been able to cross 
the threshold of delivering oxygen at a higher liter flow than 
any other device.  Vapotherm 2000i (Figure 1) is an oxygen 
delivery device that can deliver a gas flow of up to 40LPM 
while providing 100% relative humidity.  The device is 
indicated for patients who are able to maintain a normal 
Figure 1.  Vapotherm 2000i 
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carbon dioxide level but are suffering from poor oxygenation (Price, Plowright, 
Makowski, & Misztal, 2008).  This could also aid in better ventilation perfusion 
matching.  The device consists of a temperature control unit, a vapor transfer cartridge, a 
heated delivery tube, and a patient interface (Vapotherm 2000i, n.d.).  Other items needed 
are a medical gas blender and sterile water.  The device functions by heating the sterile 
water to a temperature of 33-43°C.  Once at temperature, the gas water vapor enters the 
disposable vapor transfer cartridge which is filled by hollow tubes.  The mixed medical 
gas travels through the tubes within the vapor transfer cartridge and is humidified with 
the gas water vapor.  It is then transported to the patient via a water jacketed circuit which 
is also heated in order to prevent the loss of humidity of the inspired gas.  In a study 
performed by Waugh and Granger (2004), the Vapotherm produced 43.3 mgH2O/L for all 
measured flowrates.  The patient interface is separate and interchangeable of the delivery 
tube.  The patient interface is a nasal cannula with large nasal openings that is worn in the 
same manner as a low-flow nasal cannula.  The device can be used with neonates, 
pediatric, and adult patients.  Due to the high level of humidity, most patients are able to 
tolerate the increased flows provided by the Vapotherm.  It has been shown to reduce 
respiratory rates, reduce the use of NiPPV, and the need for positive pressure ventilation 
(PPV) (Calvano, Sill, Kemp, & Chung, 2008).  Also, Turnbull (2008) demonstrated 
through a collection of case studies how high flow nasal therapy can stop the progression 
of respiratory decline and artificial ventilation.   
 
 10 
 
Optiflow 
Another device currently available is the Optiflow gas system (Fisher and Paykel, 
Auckland, New Zealand).  The Optiflow (Figure 2) can deliver up to 50LPM when 
connected to a high flow source (Fisher and Paykel Healthcare:  Patient Interfaces, n.d.).  
Optiflow is adaptable to different flow generators.  Optiflow may be driven via a high-
flow flowmeter or a blender just as other high flow 
devices. However, Optiflow can also be used in 
conjunction with continuous positive airway pressure 
(CPAP) generators.  This allows the Optiflow system 
to be used in many different areas including the 
home.  A heater must also be used in conjunction 
with this device.  Used with a Fisher and Paykel 
heater set at 37 degrees Celsius and a heated 
inspiratory limb, 44mgH2O/L of water content can be 
delivered (Parke, McGuiness, & Eccleston, 2009).  The Optiflow is a traditional heated 
bath system incorporating no new design; however, it does allow increased flow over 
traditional nasal cannula systems.  The scope of this device is for adult patients and no 
neonatal information existed in the literature.  Clinically, these devices can be utilized to 
treat many different pathologies. 
 
 
Figure 2.  Optiflow HFNC            
        (Fisher & Paykel Healthcare, 2009) 
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Clinical Uses 
High-flow nasal oxygen is capable of treating numerous ailments.  For the most 
part, high-flow oxygen was viewed as a modality to provide supplemental oxygen to 
hypoxic patients.  Since the introduction of the Vapotherm 2000i, high-flow heated 
oxygen has become a therapy within itself.  Vapotherm has had a significant role in 
treating chronic obstructive pulmonary disease (COPD) and asthma (Price, Plowright, 
Makowski, & Misztal, 2008).  The high flow may generate positive pressure that can help 
alleviate collapsed or narrowed bronchioles allowing trapped gas to escape.  Other 
published uses of Vapotherm include ventilatory failure, congestive heart failure (CHF), 
trauma, myocardial infarction (MI), and hypothermia (Turnbull, 2008).  The suspected 
reasoning why Vapotherm therapy helps treat the pathologies is due to the humidified 
gas.  Without the 100% humidity supplied to the gas by the Vapotherm unit, it is doubtful 
that patients would be able to tolerate such high gas flows.   
Vapotherm has gained popularity for treatment of hypothermia victims (Turnbull, 
2008).  Patients who suffer from low core body temperatures can inhale warm humidified 
air into the thoracic cavity to help re-warm the body.  Vapotherm allows the gas to be 
heated from 33 to 43°C facilitating a controlled warm-up.  Vapotherm can also be 
utilized to enhance the transition from mechanical ventilation to spontaneous breathing 
without artificial airway (Turnbull, 2008; Woodhead, Lambert, Clark, & Christensen, 
2006).  This has been reported for neonatal, pediatric, and adult patients.  As reported by 
Woodhead, Lambert, Clark, and Christensen (2006) no neonates given humidified high-
 12 
 
flow oxygen via Vapotherm required re-intubation.  Along with the humidity provided by 
Vapotherm, it is also believed that the generation of a higher than normal mean airway 
pressure is a byproduct of the high liter flow which plays an active role in Vapotherm 
therapy.  Studies have shown an increase in mean airway pressure in patients who are on 
Vapotherm therapy (Groves & Tobin, 2007).  This phenomenon helps explain the success 
in obstructive pathologies and CHF patients.  COPD and asthma patients benefit from the 
humidified gas but may benefit greater from the continuous positive airway pressure 
(CPAP) generated by the high flows of Vapotherm (Ai-Ping, Lee, & Lim, 2005).  By 
increasing airway pressure, the bronchioles are stabilized thus allowing trapped air to 
escape and reverse the condition of air trapping.  Another health issue that Vapotherm 
has been helpful in treating is the need for high FiO2 by patients suffering from mental 
pathologies such as claustrophobia and dementia.  Patients suffering from claustrophobia 
generally may not tolerate oxygen by mask or noninvasive positive pressure ventilation 
(NiPPV) due to the feeling of smothering caused by the mask touching the face.  
Vapotherm provides the higher FiO2 without the mask as long as the patient does not 
breathe through their mouth.  Patients suffering from impairments such as dementia often 
instinctively remove oxygen devices from their face.  In one such case described by 
Calvano, Sill, Kemp, and Chung (2008), a patient who did not tolerate oxygen mask 
therapy to treat hypoxemia was placed on Vapotherm with a significant improvement in 
the measured PaO2 and observed respiratory rate.   
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HFNC may be used to treat many different pathologies.  Evidence exists 
supporting the role of high humidity in this therapy's success.  However, if positive 
pressure is generated by HFNC, then positive pressure must also be considered as an 
element leading to the success of this therapy.   
High Flow Generates Positive Pressure 
Current modalities are changing the methods of healthcare delivery.  Patients in 
the past suffering from respiratory failure had only one choice, the ventilator; however, 
with the development of noninvasive ventilation (NIV), the pathway to recovery for 
many has changed.  NIV requires cooperative patients who will tolerate wearing a tightly 
fitted mask.  If they are unable to tolerate the mask, their only alternative is invasive 
ventilation.  NIV uses high flow rates and a sealed mask to generate pressure to augment 
ventilation.  If positive pressure is generated by high flow nasal oxygen, an alternative 
delivery method may increase the tolerance of NIV.   
The Vapotherm 2000i has not been used in any published studies to determine if 
positive pressure is generated with adult subjects.  However, research does exist detailing 
that Vapotherm produces positive pressure in neonatal and pediatric subjects.  Calvano, 
Sill, Kemp, and Chung (2008) note in their literature review that high flow nasal oxygen 
has been proven to be equivalent to noninvasive CPAP therapy in pediatrics.  This is also 
the conclusion arrived in a similar study performed on neonates (Sreenan, Lemke, 
Hudson-Mason, & Osiovich, 2001).  The positive pressure generated by high flow nasal 
therapy is variable and patient dependent.  Many factors weigh on the degree of positive 
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pressure produced.  Open mouth, closed mouth, respiratory rate, volume of breath, and 
depth of cannula in nares can influence the level of positive pressure.   
The Optiflow has been the focus of two published studies.  All studies have been 
performed outside the United States.  The Australian study concluded that high flow 
nasal oxygen produces an increased oropharyngeal pressure when compared to 
conventional therapies (Groves & Tobin, 2007).  A similar study performed by Auckland 
City Hospital in Auckland, New Zealand concluded the same results (Parke, McGuiness, 
& Eccleston, 2009).  Groves and Tobin (2007) used 5 healthy males and 5 healthy 
females placed on Optiflow system at flows starting at 0LPM up to 60LPM.  
Measurements taken via a 10 French nasal catheter were recorded.  They concluded that 
increasing nasal flow also increases oropharyngeal pressure.  Their research concluded 
that breathing with a closed mouth generates 5.5 cmH2O pressure at 40LPM flow and 7.4 
cmH2O at 60LPM (Groves & Tobin, 2007).  Adult male pressures were less than adult 
female pressures which may be attributed to nasal orifice size.  
Parke, McGuiness, and Eccleston (2009) conducted a study using 15 post cardiac 
operative patients for the study group.  This group had a 10 French nasal catheter placed 
while under anesthesia.  Recordings were made the morning following surgery with no 
set amount of time stated.  Their results were presented as group mean only and showed a 
mean oropharyngeal positive pressure of 2.70 cmH2O at 35LPM with closed mouths 
(Parke et al., 2009).  The study concluded that high flow nasal therapy produces low level 
positive airway pressure at 35LPM.  Park et al. (2009) also noted that the variability of 
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airway pressures observed in their study was most likely attributed to varying nasal 
orifice sizes.  However, generation of positive airway pressure resulted in the generation 
of positive end expiratory pressure (PEEP) and increased MPAW. 
Mean Airway Pressure 
Mean airway pressure (MPAW) is generally associated with mechanical ventilation.  
It is a relationship of pressure over time.  However, if airway pressure is increased by a 
noninvasive source, theoretically MPAW is also increased.  The difficulty in calculating 
MPAW in noninvasive ventilatory patients is the unknown time constants associated with 
spontaneous respiration.  MPAW is defined as inspiratory time (TI) multiplied by peak 
inspiratory pressure (PIP) plus expiratory time (TE) multiplied by peak end expiratory 
pressure (PEEP) divided by total cycle time (Ttot).  The written formula appears as MPAW= 
(TI x PIP)+(TE x PEEP)/Ttot.  Without the ability to set or measure the time constants 
associated with breathing, MPAW calculations are not possible.   
Conclusion 
HFNC is an accepted treatment for hypoxia.  HFNC also has been documented to 
produce CPAP in pediatric and neonatal applications.  A limited body of literature exists 
supporting its use in the adult population.  HFNC has the potential to lower the cost of 
treatment for some diseases.  It reduces cost by preventing the need for invasive 
procedures such as mechanical ventilation and the associated risk of infections.   But 
many questions remain as to how best use this therapy in the adult environment.  Further 
study of the pressure effect produced by HFNC is needed.  Starting points for flow 
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selection need to be determined so that MPAW can be targeted to treat specific pathologies.  
There is a need to compare the Vapotherm 2000i and the Optiflow to determine if both 
devices produce the same outcome. Many questions concerning this emerging therapy 
remained unanswered. 
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CHAPTER III 
RESEARCH METHODS 
The purpose of this study was to measure pressures associated with high flow 
nasal cannula (HFNC) system during spontaneous breathing.  Specifically, the study is 
designed to address the question does increasing flow to a HFNC increase mean airway 
pressure.  Spontaneous breathing is associated with negative intrathoraic pressure.  To 
produce this type of respirations in vitro, a ventilator was used to ventilate one side of a 
double lung model.  Figure 3 demonstrates the set-up used for this study.  Side A of the 
double lung was positive pressure ventilated which mechanically raised side B of 
Figure 3.  Testing Model set-up with Optiflow HFNC 
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artificial lung via a board clamped at the outer edges.  Side B of the artificial lung 
represents a negative pressure model.  A double lumen 41 French oral endotracheal tube 
(Figure 4) trimmed to the upper cuff was used to simulate the nares of the model.  The 
cuff was inflated to seal inside a 6 inch 22mm internal diameter vinyl tubing.   A 22mm 
outside diameter pressure line adaptor was connected to the other end of vinyl tubing 
which was connected to the test lung 
tubing.  The HFNC was setup to 
manufacturer specifications minus 
humidity and powered by a high flow 
oxygen flow meter designed to deliver flow 
up to 80 liters per minute (LPM).  The 
nasal cannula was positioned via a clamp so 
that the cannulas were slightly inserted into 
the in vitro nose.  Flow through the HFNC system was manipulated at 20, 30, and 40 
LPM flowrates.  Measurements were taken via small bore oxygen tubing by the auxiliary 
pressure monitor port on the Galileo ventilator.    
Lung Model 
 In this study, an in vitro lung model as seen in Figure 3 was used to simulate adult 
patient respiration.  The Michigan Instruments Labs (MIL) Dual Adult TTL Lung 
(Michigan Instruments, Inc. Grand Rapids, Michigan) was used in conjunction with an 
Figure 4 
41 French double lumen endotracheal tube 
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adult ventilator.  The MIL adult lung has 2 independent chambers that can be 
independently ventilated.  Compliance was manipulated independently.  Compliance of  
0.5L/cmH2O was used for the study for both the positive pressure and negative pressure 
chambers.  No resistors were used in this study. 
Ventilator 
 A Hamilton Galileo Gold ventilator (Hamilton Medical, Inc. Reno, Nevada) was 
used with a standard 72 inch adult circuit (Figure 5).  The Hamilton Galileo is a 
microprocessor based ventilator.  The Galileo was chosen because of an accessory 
auxiliary pressure port located on the front of the ventilator.  Ventilator settings were 
chosen to mimic adult ventilation.  Two sets of 
parameters were chosen to simulate non-labored 
and labored breathing.  Non-labored parameters 
were respiratory rate of 12, 450mL tidal volume, 
no PEEP, 21% oxygen, and a flowrate of 35LPM 
which yielded an inspiratory/expiratory (I:E) ratio 
of 1:3.1.  Labored parameters were a respiratory 
rate of 24, 450ml tidal volume, no PEEP, 21% 
oxygen, and a flowrate of 65LPM which yielded a 
I:E ratio of 1:2.8.  The Hamilton Galileo was 
calibrated per manufacturer guidelines before use Figure 5 
Hamilton Galileo Gold 
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in this study.  The ventilator was connected directly to side A of the MIL lung.    
Parameters manipulated during this study were respiratory rate and flow.  Flow was 
manipulated to produce inspiration/expiration ratios (I:E Ratio) similar to normal 
breathing.  All other parameters remained constant. 
Fabricated High-flow Device 
 The fabricated high-flow device seen in Figure 6 was constructed of materials 
found available in a respiratory therapy department.  The device consisted of products 
manufactured by Hudson RCI (Teleflex Medical, Research Triangle Park, NC).  The 
device consisted of Hudson Concha 
4 heater column with nipple 
adaptor.  This was connected to a 
heated wire circuit also 
manufactured by Hudson RCI.  The 
circuit was connected to a Salter 
Labs HFNC (Salter Labs, Inc. 
Arvin, CA) via a second nipple adaptor.  The Salter Labs HFNC was chosen because it is 
designed to deliver flows of 6-15 LPM. 
Data Collection 
Data was collected in accordance to the protocols listed in Appendix A and 
Appendix B.  Data was monitored via the Galileo ventilator.  Three pressures were 
recorded for this study.  The minimum pressure (PMIN) represents the lowest pressure 
Figure 6 
Generic HFNC 
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generated during the breath.  Positive end-expiratory pressure (PEEP) and positive 
inspiratory Pressure (PIP) were recorded.  After the warm-up periods described by the 
protocols were completed, recordings from 12 breaths were recorded.   
From the data collected, mean airway pressure (MPAW) was able to be calculated.  
Calculations were possible due to the known time constants of the recorded breaths.  
Using the formula MPAW= (TI x PIP)+(TE x PEEP)/Ttot, MPAW was calculated for all 
breaths. 
Data Analysis 
 Data was analyzed using SPSS for Windows (version 16.0).  The data analysis 
included a one way ANOVA, a Bonferroni test, and descriptive statistics.   
Conclusion 
 The research methods were directed by two study questions: (1) Does increasing 
flow through a high flow nasal cannula increase MPAW? and (2) does the devices used in 
this study yield results that are statistically different?  A Hamilton Galileo, with auxiliary 
port pressure monitoring, was used in this study.  The Hamilton Galileo is capable of 
measuring pressures to the tenth of a centimeter of water pressure.  A MIL adult dual test 
lung was also used in this study.  The ventilator was used to ventilate one chamber of the 
test lung which triggered a spontaneous negative breath in the second chamber via a 
clamped board.  A 41 French double lumen endotracheal tube trimmed to the high cuff 
was used to simulate the nares.  The study focused on the Vapotherm 2000i with adult 
transfer chamber, Optiflow, and a generic built high flow nasal cannula system.    
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Chapter IV 
Results 
 The primary focus of this study was the effect of increasing flow to a high flow 
nasal cannula (HFNC) on mean airway pressure (MPAW).  The research was also directed 
by the research question:  Are the outputs of two commercial devices, the Vapotherm 
2000i and Optiflow, and a high flow system constructed of available equipment from a 
respiratory therapy department, statistically different?   
 Analysis was performed using descriptive statistics and a one way ANOVA.  Post 
hoc analysis utilizing a Bonferroni was also used.  Descriptive statistics for non-labored 
and labored breathing can be seen in Table 1 and 2. 
Non-Labored Statistics 
 N Mean Std. Deviation Variance 
FLOW20LPM 36 .467 .1265 .016 
FLOW30LPM 36 1.503 .3282 .108 
FLOW40LPM 36 2.981 .4880 .238 
Table 1.  Descriptive analysis of non-labored breathing by liter flow. 
 
Labored Statistics 
 N Mean Std. Deviation Variance 
FLOW20LPM 36 .444 .0607 .004 
FLOW30LPM 36 1.542 .1156 .013 
FLOW40LPM 36 3.144 .1963 .039 
Table 2.  Descriptive analysis of labored breathing by liter flow. 
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For this study, 72 MPAW calculations were recorded.  As shown in Tables 1 and 2, 
the statistical mean for all 3 flowrates were positive indicating MPAW was increased when 
on HFNC.  The statistical mean trends upward as flow increases.  Figures 7 and 8 
provides side by side comparison of the devices depicting MPAW for each device at the 
three liter flows recorded for non-labored and labored breathing patterns.   
 
 
            Figure 7.  Device Comparison of Mean Airway Pressure for  
                   non-labored breathing pattern 
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 Figure 8.  Device Comparison of Mean Airway Pressure for  
                   labored breathing pattern 
One way ANOVA results can be found in Table 3.  The overall effects were 
significant F (5,66) = 191.481, 1237.704, and 1975.356 respective to liter flow.  p = 
0.000 for all flowrate comparisons.  Further analysis via Bonferroni adjusted probabilities 
can be found in Tables 4, 5, and 6.  The Bonferroni adjusted probabilities determined all 
comparisons were significant except for Vapotherm-Vapotherm Labored at 30 and 40 
LPM flow rates and Vapotherm-Generic Labored at 20 LPM.  These three comparisons 
all were at the p > 0.05 level.  At this level, the devices produced the same outcome in 
regards to MPAW.  All other comparisons had significant differences at the p < 0.05 level.   
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Table 3.  One way ANOVA analysis 
  Sum of Squares df Mean Square F Sig. 
FLOW20LPM Between Groups .653 5 .131 191.481 .000 
Within Groups .045 66 .001   
Total .698 71    
FLOW30LPM Between Groups 4.219 5 .844 1237.704 .000 
Within Groups .045 66 .001   
Total 4.264 71    
FLOW40LPM Between Groups 10.101 5 2.020 1975.356 .000 
Within Groups .068 66 .001   
Total 10.169 71    
 
 
Table 4.  Pairwise analysis of 20LPM flowrate data 
 VT20 OF20 GEN20 VT20LAB OF20LAB GEN20LAB 
VT20  .2000* -.1000* .1083* .0667* -.0083t 
OF20 -.2000*  -.3000* -.0917* -.1333* -.2083* 
GEN20 .1000* .30008  .2083* .1667* .0917* 
VT20LAB -.1083* .0917* -.2083*  -.0417* -.1167* 
OF20LAB -.0667* .1333* -.1667* .0417*  -.0750* 
GEN20LAB .0083t .2083* -.0917 .1167* .0750*  
VT20=Vapotherm 20LPM OF20=Optiflow 20LPM GEN20=Generic 20LPM 
VT20LAB=Vapotherm 20LPM Labored OF20LAB=Optiflow 20LPM Labored 
GEN20LAB=Generic 20LPM labored    *p<0.05    t = p > 0.05 
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Table 5.  Pairwise analysis of 30LPM flowrate data 
 VT30 OF30 GEN30 VT30LAB OF30LAB GEN30LAB 
VT30  .3917* -.4000* .0000t .0667* -.1917* 
OF30 -.3917*  -.7917* -.3917* -.3250 -.5883 
GEN30 .4000* .7917*  .4000* .4667* .2083 
VT30LAB .0000t .3917* -.4000*  .0667* -.1917* 
OF30LAB -.0667* .3250* -.4667* -.0667*  -.2583* 
GEN30LAB .1917* .5833* -.2083* .1917* .2583*  
VT30=Vapotherm 30LPM OF30=Optiflow 30LPM GEN30=Generic 30LPM 
VT30LAB=Vapotherm 30LPM Labored OF30LAB=Optiflow 30LPM Labored 
GEN30LAB=Generic 30LPM labored    *p<0.05    t = p > 0.05 
 
Table 6.  Pairwise analysis of 40LPM flowrate data 
 VT40 OF40 GEN40 VT40LAB OF40LAB GEN40LAB 
VT40  .7583* -.4000* .0083t .1583* -.3000* 
OF40 -.7583*  -1.1583* -.7500* -.6000* -1.0583* 
GEN40 .4000* 1.1583*  .4083* .5583* .1000* 
VT40LAB -.0083t .7500* -.4083*  .1500* -.3083* 
OF40LAB -.1583* .6000* -.5583* -.1500*  -.4583* 
GEN40LAB .3000* 1.0583* -.1000* .3083* .4583*  
VT40=Vapotherm 40LPM OF40=Optiflow 40LPM GEN40=Generic 40LPM 
VT40LAB=Vapotherm 40LPM Labored OF40LAB=Optiflow 40LPM Labored 
GEN40LAB=Generic 40LPM labored    *p<0.05    t = p > 0.05 
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Conclusion 
In conclusion, the results of this study answered the two questions.  As seen in 
Figure 1, HFNC systems produce a positive MPAW at the 20, 30, and 40LPM flowrates.  
The one way ANOVA analysis indicates that there is a statistical significance in the 
outcomes of the devices used in this study.  The generic HFNC system produced a MPAW 
consistently higher than the Vapotherm or Optiflow at all liter flows.  All values for the 
generic system were significantly greater when compared to other devices.   
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Chapter V 
Discussion 
This study was designed to answer two research questions.  The primary question 
was to evaluate the relationship of flow via a high flow nasal cannula (HFNC) on mean 
airway pressure (MPAW) in an adult model.  The second question was to evaluate the 
MPAW pressures generated by three HFNC systems.  The study compared the Vapotherm 
2000i, the Optiflow, and a system constructed of different parts stocked in a hospital 
respiratory department. 
 Using the in vitro model, breathing was simulated and recordings were made 
using three different high flow systems.  Average MPAW for all three liter flows were 
greater than 0 cmH2O for all systems.  MPAW averages for 20LPM, 30LPM, and 40LPM 
were 0.5cmH2O, 1.5cmH2O, and 3.1cmH2O respectively.  These averages are inclusive 
of both the unlabored and labored groups.  It can be concluded that HFNC increases 
MPAW in the in vitro model.  It can also be deducted that HFNC produces PEEP in this 
model based on the mathematical formula MPAW= (TI x PIP)+(TE x PEEP)/Ttot.  In this 
study, the expiratory time (TE) was 2.8 to 3.1 times greater than the inspiratory time (TI).  
Therefore, for MPAW to be positive PEEP must be present. 
 Side by side comparison of the devices at the different flow rates yielded 
additional information.  The three devices were compared by the MPAW delivered.  The 
two commercially available devices, Vapotherm and Optiflow, were compared and 
determined that Vapotherm produces a higher MPAW than Optiflow in this study.  When 
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the generic HFNC system was compared to the commercial systems, the generic 
delivered a higher MPAW than either the Vapotherm or Optiflow.  At 40LPM, the highest 
MPAW was produced and the generic system produced the highest average pressure at 
3.65cmH2O.  Vapotherm averaged 3.1cmH2O and Optiflow produced 2.65cmH20.  One 
way ANOVA also showed the differences were statistically significant as the liter flow 
increased.  As flow increased, the F ratio also increased.  Post hoc Bonferroni adjusted 
probabilities were compared in pairwise tables.  When comparing the three devices, it can 
be concluded that the generic system was superior in terms of MPAW and the Vapotherm 
produced a higher MPAW than the Optiflow system in this study.   
This study controlled all variables in order to isolate MPAW.  Similar studies using 
HFNC systems used human subjects and were unable to calculate MPAW (Groves & 
Tobin, 2007).  Parke, McGuiness, and Eccleston (2009) performed a study that concluded 
35LPM flow via the Optiflow generated 2.70cmH2O of MPAW; however, stated in the 
study as a limitation was the uncertainty that the pressure was MPAW even though the 
researchers named the pressure MPAW.  Parke et al. (2009) did refer to the recorded 
pressure as MPAW.  Parke et al. (2009) recordings at 35LPM fall between the two data 
averages recorded in this study.  However, the in vitro model study average MPAW 
pressures for 30 and 40LPM are 1.5cmH2O and 3.1cm H2O respectively and the two 
studies do correlate.  Unfortunately, Parke et al. (2009) did not include data to reproduce 
their findings at the liter flow described.  Respiratory rates, tidal volumes, and breathing 
styles were unknown for the Parke et al. (2009) study.   
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Groves and Tobin (2007) utilized the Optiflow system at flows of 40 and 60LPM.  
They used healthy males and females and recorded average expiratory pressures of 
5.5cmH2O and 7.4cmH2O, respectively.  When compared to the in vitro study at 40LPM, 
a significant difference can be seen.  The Optiflow system averaged 2.7cmH2O at 40LPM 
using the in vitro lung model.  The generic system produced the highest average MPAW at 
3.5cmH2O which is still lower than the study conducted by Groves and Tobin (2007).  
Groves and Tobin measured oropharyngeal pressure and not MPAW.  This could be 
attributed to differences in pressures recorded.  This study isolated variables such as time 
constants in order to calculate MPAW.  Groves and Tobin (2007) used healthy human 
subjects to collect data.  Pressures presented by Groves and Tobin cannot be a calculated 
MPAW average as spontaneous breathing subjects cannot breathe in a manner to isolate 
inspiratory and expiratory time constants.   
HFNCs do not function as a normal nasal cannula.  It is capable of providing a 
higher FiO2 concentration as well as increased pressures.  The increased flow generates 
resistance to expiratory flow thereby increasing MPAW.  Increased MPAW can be utilized to 
treat patients suffering from ailments such as COPD exacerbations, congestive heart 
failure (CHF), or hypoxic failure.  Correct utilizations of the therapy are also important 
and an understanding of the physiological effects must be understood by respiratory 
therapists using this therapy.   
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Limitations 
There are limitations to any study performed.  Many limitations have been 
identified for this study.  The following limitations have been taken into account by the 
researcher for this study. 
1.  In vitro study findings can be difficult to generalize due to the fact that a 
bench model is not an actual person.  The simulator may not model the actual 
condition being studied. 
2. The artificial nose and airway is not physiologically correct.  In an actual 
human subject, the flow introduced by a HFNC will meet a much higher level 
of resistance as the flow is introduced to the human nose.  This could account 
for the differences.   
3. The design of the artificial nose could also influence flow in a laminar pattern.  
It is reasonable to consider that flow through a human nose may be more 
turbulent in nature and thereby increase resistance to expiratory flow. 
4. The model is not to scale in terms of length when compared to a physiological 
model.  The model is constructed of noncompliant smooth vinyl with little 
resistance.  The tracheal rings that are present in a human subject could 
increase resistance or influence turbulent flow. 
5. Orifice sizes of the cannulas were not measured for this study.  There is a 
possibility that the nasal cannulas could have different orifice sizes which 
could influence MPAW levels. 
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6. No tests included humidity.  Vapotherm and Optiflow are both documented to 
provide 100% relative humidity (Waugh & Granger, 2004; Parke, McGuiness, 
& Eccleston, 2009).  Therefore, the tests were not conducted using humidity.  
The generic system was not tested for relative humidity produced.  It is a 
possibility that the comparison is unreasonable as this system may fail to 
deliver 100% relative humidity.  Also, the humidified air may have a larger 
molecular makeup when compared to the dry gas used in this study.  The 
larger molecular makeup of humidified gas could produce a higher MPAW. 
Need for further Research 
Further research evaluating HFNC systems should be performed to better 
understand the effect in adult patients.  A comparison study needs to be performed using 
adult subjects to further evaluate the devices used in this study.  There is a lack of 
literature pertaining to adults and HFNC therapy. 
Research exists in the neonatal and pediatric populations where HFNC therapy 
has found a high level of success.  Kubicka, Limauro, and Darnall (2008) performed a 
bench study and human trials with HFNC on neonates.  Bench study measurements were 
conducted with an anesthesia bag with an estimated leak to represent a patient's nose and 
mouth.  They observed HFNC producing 4.5cmH2O at 8.0LPM flow in vitro (Kubicka et 
al., 2008).  When the study was transitioned to in vivo they discovered that 4.0LPM flow 
generated 4.3 to 4.8cmH2O oral cavity pressure with a closed mouth (Kubicka et al., 
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2008).  Weiner et al. (2008) also reported oral cavity pressures ranging from 2.5 to 
3.5cmH2O at the 5.0LPM flow.   
For this study, however, it must be noted that it is difficult to compare adults to 
neonates due to differences in physiological features.   Many nasal cannulas used in high-
flow therapy are snug in the nares which may contribute to a higher level to pressure.  
Also, the nasopharyngeal cavity is much smaller and may provide a lower level of 
resistance.  Adult patient nares have a larger opening and are not likely to be occluded by 
a nasal cannula.  Adults also have a much larger nasopharyngeal cavity to distribute the 
flow generated by HFNC.  Due to these physiological differences, neonatal and pediatric 
studies do not offer an effective comparison for adult interpretation. 
There is also a need for an evaluation of devices constructed to deliver high flow 
therapy to determine if they are capable of delivering the high levels of humidity that the 
Vapotherm and Optiflow systems are capable of.  This therapy is a combination of two 
therapies, humidity and high flow.  Any system constructed must be capable of providing 
both.   
Conclusion 
HFNCs are a new spin on an old device.  They provide a level of humidity that 
was once only delivered with closed systems.  HFNCs deliver flows that exceed the scale 
on most flow meters.  They deliver FiO2 percentages higher than some of the masks that 
have been used for many years in respiratory care.  It cannot be assumed by respiratory 
therapists that they only deliver oxygen. 
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As this study has shown, HFNCs have a profound physiological effect.  HFNC 
produce PEEP and increase MPAW.  As flow increases, MPAW also increases.  This has the 
potential to be an effective therapy for numerous ailments in the adult population.  HFNC 
profoundly affected care in the pediatric and neonatal populations.  HFNC does possess 
the ability to do the same for adult patients. 
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Appendix A 
Protocol 
Non-labored Breathing 
 
1. Power on Galileo Ventilator 
2. Run manufacturer flow-sensor calibration 
3. Program ventilator with selected parameters 
a. Respiratory rate of 12 
b. Tidal volume 400 
c. Flow of 35LPM  
i. Produces I:E of 1:3.1 
d. Sine Waveform 
e. Oxygen 21% 
f. No PEEP 
4. Connect ventilator circuit to positive pressure side of test lung 
a. Lung compliance set at 0.5 L/cmH2O 
5. Activate auxiliary pressure port 
a. Connect auxiliary pressure line to front of ventilator 
b. Connect auxiliary pressure line to adaptor placed in negative airway 
6. Start ventilator and allow to cycle for 1 minute 
7. Start Measurement of control with no cannula at the orifice of double lumen tube 
Vapotherm  
 
1.  Recalibrate Galileo flowsensor 
2. Allow to cycle for 1 minute 
3. Connect Vapotherm unit to H cylinder and turn flow to 20 LPM via high flow 
flow-meter 
4. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
5. After cannula in place cycle ventilator for 1 minute 
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
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7. Recalibrate Galileo flowsensor 
8. Allow to cycle for 1 minute 
9. Connect Vapotherm unit to H cylinder and turn flow to 30 LPM via high flow 
flow-meter 
10. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
11. After cannula in place cycle ventilator for 1 minute 
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
13. Recalibrate Galileo flowsensor 
14. Allow to cycle for 1 minute 
15. Connect Vapotherm unit to H cylinder and turn flow to 40 LPM via high flow 
flow-meter 
16. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
17. After cannula in place cycle ventilator for 1 minute 
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
 Optiflow 
 
1. Recalibrate Galileo flowsensor 
2. Allow to cycle for 1 minute 
3. Connect Optiflow unit to H cylinder and turn flow to 20 LPM via high flow flow-
meter 
4. Position adult nasal Optiflow cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
5. After cannula in place cycle ventilator for 1 minute 
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
7. Recalibrate Galileo flowsensor 
8. Allow to cycle for 1 minute 
9. Connect Optiflow unit to H cylinder and turn flow to 30 LPM via high flow flow-
meter 
10. Position adult nasal Optiflow cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
11. After cannula in place cycle ventilator for 1 minute 
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
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13. Recalibrate Galileo flowsensor 
14. Allow to cycle for 1 minute 
15. Connect Optiflow unit to H cylinder and turn flow to 40 LPM via high flow flow-
meter 
16. Position adult nasal Optiflow cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
17. After cannula in place cycle ventilator for 1 minute 
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
Generic HFNC 
 
1. Recalibrate Galileo flowsensor 
2. Allow to cycle for 1 minute 
3. Connect Generic unit to H cylinder and turn flow to 20 LPM via high flow flow-
meter 
4. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
5. After cannula in place cycle ventilator for 1 minute 
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
7. Recalibrate Galileo flowsensor 
8. Allow to cycle for 1 minute 
9. Connect Generic unit to H cylinder and turn flow to 30 LPM via high flow flow-
meter 
10. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
11. After cannula in place cycle ventilator for 1 minute 
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
13. Recalibrate Galileo flowsensor 
14. Allow to cycle for 1 minute 
15. Connect Generic unit to H cylinder and turn flow to 40 LPM via high flow flow-
meter 
16. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
17. After cannula in place cycle ventilator for 1 minute 
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
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Appendix B 
Protocol 
Labored Breathing 
 
1. Power on Galileo Ventilator 
2. Run manufacturer flow-sensor calibration 
3. Program ventilator with selected parameters 
a. Respiratory rate of 24 
b. Tidal volume 400 
c. Flow of 65LPM  
i. Produces I:E of 1:2.8 
d. Sine Waveform 
e. Oxygen 21% 
f. No PEEP 
4. Connect ventilator circuit to positive pressure side of test lung 
a. Lung compliance set at 0.5 L/cmH2O 
5. Activate auxiliary pressure port 
a. Connect auxiliary pressure line to front of ventilator 
b. Connect auxiliary pressure line to adaptor placed in negative airway 
6. Start ventilator and allow to cycle for 1 minute 
7. Start Measurement of control with no cannula at the orifice of double lumen tube 
Vapotherm 
 
1. Recalibrate Galileo flowsensor 
2. Allow to cycle for 1 minute 
3. Connect Vapotherm unit to H cylinder and turn flow to 20 LPM via high flow 
flow-meter 
4. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
5. After cannula in place cycle ventilator for 1 minute 
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
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7. Recalibrate Galileo flowsensor 
8. Allow to cycle for 1 minute 
9. Connect Vapotherm unit to H cylinder and turn flow to 30 LPM via high flow 
flow-meter 
10. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
11. After cannula in place cycle ventilator for 1 minute 
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
a. Start recording on breath number 2 
b. Record even number breaths for total of 12 recordings (n=12) 
13. Recalibrate Galileo flowsensor 
14. Allow to cycle for 1 minute 
15. Connect Vapotherm unit to H cylinder and turn flow to 40 LPM via high flow 
flow-meter 
16. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
17. After cannula in place cycle ventilator for 1 minute 
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
a. Start recording on breath number 2 
b. Record even number breaths for total of 12 recordings (n=12) 
Optiflow 
 
1. Recalibrate Galileo flowsensor 
2. Allow to cycle for 1 minute 
3. Connect Optiflow unit to H cylinder and turn flow to 20 LPM via high flow flow-
meter 
4. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
5. After cannula in place cycle ventilator for 1 minute 
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
7. Recalibrate Galileo flowsensor 
8. Allow to cycle for 1 minute 
9. Connect Optiflow unit to H cylinder and turn flow to 30 LPM via high flow flow-
meter 
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10. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
11. After cannula in place cycle ventilator for 1 minute 
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
a. Start recording on breath number 2 
b. Record even number breaths for total of 12 recordings (n=12) 
13. Recalibrate Galileo flowsensor 
14. Allow to cycle for 1 minute 
15. Connect Optiflow unit to H cylinder and turn flow to 40 LPM via high flow flow-
meter 
16. Position adult nasal Vapotherm cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
17. After cannula in place cycle ventilator for 1 minute 
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
a. Start recording on breath number 2 
b. Record even number breaths for total of 12 recordings (n=12) 
Generic HFNC 
 
1. Recalibrate Galileo flowsensor 
2. Allow to cycle for 1 minute 
3. Connect Generic unit to H cylinder and turn flow to 20 LPM via high flow flow-
meter 
4. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
5. After cannula in place cycle ventilator for 1 minute 
6. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
a. Start recording on breath number 2 
b. Record even number breaths for total of 12 recordings (n=12) 
7. Recalibrate Galileo flowsensor 
8. Allow to cycle for 1 minute 
9. Connect Generic unit to H cylinder and turn flow to 30 LPM via high flow flow-
meter 
10. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
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11. After cannula in place cycle ventilator for 1 minute 
12. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
a. Start recording on breath number 2 
b. Record even number breaths for total of 12 recordings (n=12) 
13. Recalibrate Galileo flowsensor 
14. Allow to cycle for 1 minute 
15. Connect Generic unit to H cylinder and turn flow to 40 LPM via high flow flow-
meter 
16. Position adult nasal Generic cannula with clamp stand so that nasal prongs rest 
inside double lumen tube 
17. After cannula in place cycle ventilator for 1 minute 
18. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
a. Start recording on breath number 2 
b. Record even number breaths for total of 12 recordings (n=12) 
19. After 1 minute record PMIN, PIP, and PEEP for 12 breaths (1 minute)  
a. Start recording on breath number 2 
b. Record even number breaths for total of 12 recordings (n=12) 
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